Asmaa Housni

Asmaa Housni

Auto-generated profile, based on publicly available information

Asmaa Housni

School of Human Nutrition, McGill University, Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2023 in JMIR Diabetes
Verified
Journal Article
Open access
LXLi Feng Xie
Li Feng Xie
AHAsmaa Housni
Asmaa Housni
MNMeranda Nakhla
Meranda Nakhla
RCRosemarie Cianci
Rosemarie Cianci
CLCatherine Leroux
Catherine Leroux
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau
Background: Youth (aged 14-24 years) living with type 1 diabetes (T1D) encounter increased challenges in their diabetes self-management (DSM), especially during the transition to adult care. Although DSM education and support are imperative, there is insufficient information on how web-based digital tools tailored to their demands can be developed. Objective: On the basis of the Behavior Change Wheel, this study aims to identify, among youth living with T1D, the needs and factors influencing their DSM in the context of health care transition and to inform the adaptation (content and features) of an adult self-guided web application (Support). Methods: Internet-based semistructured individual interviews based on a phenomenological study design were conducted with 21 youths, and transcripts were analyzed using an inductive approach with concept mapping. Results: Factors influencing T1D self-management were categorized into barriers and facilitators and then as external or internal. Features influencing the accessibility to information, increasing the sense of support, and use of the tool were positively accepted. Features unrelated to their expectations of digital tool use or difficulty navigating were viewed negatively. Participants expressed an interest in reliable, practical, and novel educational content. Although youth considered the information provided by medical professionals to be important, peer exchange was deemed necessary to obtain a practical perspective and real-life examples. Conclusions: Compared with the adult population, in addition to tailored content and a simplified information search process, when building a DSM education and support digital tool for youth, features should be selected to encourage supervised peer exchange.

29 August 2024 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Open access
AHAsmaa Housni
Asmaa Housni
AKAlexandra Katz
Alexandra Katz
JKJessica C. Kichler
Jessica C. Kichler
MNMeranda Nakhla
Meranda Nakhla
LSLaurence Secours
Laurence Secours
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau
This study investigates stigma predictors across ages and genders, addressing a critical gap in understanding diverse populations to reduce related suboptimal clinical and psychosocial outcomes. Cross-sectional analysis of self-reported data from BETTER, a Canadian registry of people with type 1 diabetes. Participants (n = 709) completed the 19-item-Diabetes-Stigma Assessment-Scale (DSAS-1) categorized into treated differently, blame and judgment, and identity concerns sub-scales. Associations with diabetes distress (DDS-17-score/102), depression (PHQ-9-score/27), social-support (ESSI-score/34), fear of hypoglycemia (HFS-II-score/132), and hyperglycemia-avoidance-behaviours (HAS-score/88) were computed. Perceived stigma was highest in youth aged 14-24 years (46·0 ± 15·6, p < 0·001) and women (41·2 ± 15·7, p = 0·009), compared to other age groups and men. Blame and Judgment contributed to most of stigma perception. Youth perceived significantly more blame and judgment (p < 0·001) and identity concerns (p = 0·001) compared to middle-aged adults and seniors. Women perceive significantly more blame and judgment compared to men (p < 0·001). The perception of being treated differently was not reported to be an issue across ages and genders. Participants with higher scores of depression, diabetes-distress, fear of hypoglycemia, hyperglycemia-avoidance behaviours, and lesser social-support, reported increased stigma. Stigma varies by age and gender, underscoring the need for targeted interventions to reduce it. Challenging stereotypes and reducing stigma-related stressors are essential for better outcomes.

23 May 2024 in Diabetes Care
Verified
Journal Article
Open access
PDF file
AKAlexandra Katz
Alexandra Katz
ARAmélie Roy-Fleming
Amélie Roy-Fleming
AHAsmaa Housni
Asmaa Housni
MTMeryem K. Talbo
Meryem K. Talbo
SHSarah Haag
Sarah Haag
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau
Alexandra Katz, Amélie Roy-Fleming, Asmaa Housni, Meryem K. Talbo, Sarah Haag, Rémi Rabasa-Lhoret, Anne-Sophie Brazeau; The Support-Pro Online Training Pla Alexandra Katz, Amélie Roy-Fleming, Asmaa Housni, Meryem K. Talbo, Sarah Haag, Rémi Rabasa-Lhoret, Anne-Sophie Brazeau; The Support-Pro Online Training Pla

28 March 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
AHAsmaa Housni
Asmaa Housni
AKAlexandra Katz
Alexandra Katz
LBLucien Junior Bergeron
Lucien Junior Bergeron
ASAlain Simard
Alain Simard
AFAshley Finkel
Ashley Finkel
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau
Background: Carbohydrate counting (CC) can be burdensome and difficulty with adherence has been reported. Automated CC through mobile apps offers innovative solutions to ease this burden. Objective: This cross-sectional web-based survey aims to identify (1) perceived barriers to CC by Canadians living with type 1 diabetes (T1D) and (2) app features that would help reduce these barriers. The secondary objective aims to compare apps used by participants with the suggested app features. Methods: People with T1D aged 14 years and older, living in Canada, were recruited through the BETTER Canadian registry, diabetes organizations, and social media. Participants completed a 39-question web-based survey (closed- and open-ended) to identify barriers in CC, preferred CC app features, and current app use. Respondents rated barriers and app features using a 5-point Likert scale. The features were cross-referenced in each app reported being used by participants. Descriptive statistics summarized barriers and app feature preferences, and statistical analyses identified differences by age, app use, and insulin modality. Mean scores (out of 5) were compared using 2-tailed t tests or nonparametric tests. Open-ended questions were analyzed using inductive thematic analysis. Results: Participants (N=196; woman: n=145, 74%; mean age 40 [SD 17] years; mean diabetes duration 22 (14) years; relied on CC to determine insulin doses at mealtimes: n=178, 90.8%) reported barriers related to carbohydrate identification, nutrient interaction, and insulin dose calculation, as well as psychosocial factors. Preferred app features included nutrient analysis (165/196, 84.2%), personalization (151/196, 77.1%), insulin bolus calculation (145/196, 74%), and health care professional support (135/196, 68.8%). Among the 16 apps used by participants, most (12/16, 75%) supported nutrient analysis but only one offered bolus calculations or health care professional support, and none offered personalization. Users on injections reported greater barriers to blood glucose monitoring for insulin adjustments compared to exclusive pump users (mean score of 3.87, SD 1.22 vs mean 3.30, SD 1.28; P=.001). They also expressed higher needs for meal logs in an electronic food journal (mean 4.06, SD 1.18 vs mean 3.69, SD 1.17; P=.01), bolus dose suggestions (mean 4.37, SD 0.98 vs mean 3.84, SD 1.26; P=.001), and app personalization (mean 4.47, SD 0.86 vs mean 3.93, SD 1.21; P<.001). No significant differences were observed based on age or app use. The thematic analysis revealed participants’ perceptions of suggested barriers and features, as well as new barriers such as calculation errors from unreliable food data and nutrition labels, fear of eating disorders, limited app reliability, and insufficient health care support, with suggestions for technology-based solutions. Conclusions: CC mobile apps currently used do not meet the needs of people with T1D. A novel CC app with app features such as photo recognition, reliable nutrient values, and personalized bolus calculations could reduce the CC burden.

3 January 2024 in Canadian Journal of Diabetes
Verified
Journal Article
Closed access
AHAsmaa Housni
Asmaa Housni
RCRosemarie Cianci
Rosemarie Cianci
RSRayzel Shulman
Rayzel Shulman
MNMeranda Nakhla
Meranda Nakhla
JCJoseph A. Cafazzo
Joseph A. Cafazzo
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau

12 January 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
AKAlexandra Katz
Alexandra Katz
ASAidan Shulkin
Aidan Shulkin
AHAsmaa Housni
Asmaa Housni
ARAmélie Roy‐Fleming
Amélie Roy‐Fleming
RRRémi Rabasa‐Lhoret
Rémi Rabasa‐Lhoret
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau
Glucocorticoids (GCs) are widely utilised for the treatment of inflammatory and autoimmune conditions but often precipitate significant hyperglycaemia. People with type 1 diabetes (PWT1D) may be particularly affected due to the challenges of adjusting insulin dosing, for which recommendations remain unclear. Our aim is to synthesise the evidence on the glycaemic effects of GCs in PWT1D across various formulations, doses and administration routes, and to outline management strategies. In August 2025, a systematic search of MEDLINE, Embase and CENTRAL was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta‐Analysis guidelines. Eligible studies included adult PWT1D exposed to GCs and reported glycaemic outcomes and/or management strategies. Twenty‐two studies were included, comprising 368 PWT1D. GC exposure was consistently associated with marked hyperglycaemia and increased insulin requirements. Oral and intravenous GC regimens required substantial insulin dose escalation, in many cases up to 70% from baseline. During pregnancy, antenatal corticosteroids were best managed with structured subcutaneous or intravenous insulin protocols. Local injectable GCs caused delayed but prolonged excursions and required careful blood glucose (BG) monitoring. Emerging data suggest that automated‐insulin delivery (AID) systems attenuate BG elevation but still require user intervention. Thus, GC therapy in PWT1D destabilises glycaemic management, though impact and timing vary by formulation, dose, administration route, patient‐specific factors and clinical context. Proactive, individualised insulin adjustments aligned with GC pharmacokinetics and frequent BG monitoring or continuous glucose monitor use represent the most practical current strategy. Further research is required to develop evidence‐based guidelines and to clarify the role of AID.